Intact or broken-apart RNA: An alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC)

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 1, 2015, Pages 60-70

  Kotoula, Vassiliki ^a,b   Bobos, Mattheos ^b   Vassilakopoulou, Maria ^g   Tsolaki, Eleftheria ^b   Chrisafi, Sofia ^b   Psyrri, Amanda ^d   Lazaridis, George ^a   Papadopoulou, Kyriaki ^b   Efstratiou, Ioannis ^c   Michail Strantzia, Catherine ^e   Debelenko, Larisa V ^h   Kosmidis, Paris ^f   Fountzilas, George ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Foundation for Cancer Research   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e Aglaia Kyriakou Children's Hospital   (Greece)

^f HYGEIA HOSPITAL   (Greece)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALK fusion; ALK gene copies; AQUA; FFPE; FISH; IHC; mRNA; Neuroblastoma; NSCLC; qPCR

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; MESSENGER RNA; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER TISSUE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; QUANTITATIVE ANALYSIS; STAINING; TUMOR GENE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC ERROR; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC ERRORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84917691332     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000028     Document Type: Article

References (31)

1. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9: 331-356.
2. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
3. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13:685-700.
4. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156: 1711-1721.
5. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma - preclinical and clinical advancements. Nat Rev Clin Oncol. 2012; 9:391-399.
6. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279-284.
7. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov. 2011;10:897-898.
8. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415-453.
9. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461:245-257.
10. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581-5590.
11. Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non small cell lung cancer. Cancer. 2012; 118:4486-4494.
12. McLeer-Florin A, Lantuejoul S. Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. J Thorac Dis. 2012;4:240-241.
13. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
14. Soda M, Isobe K, Inoue A, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18:5682-5689.
15. Kotoula V, Krikelis D, Karavasilis V, et al. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer. 2012;12:342.
16. Fountzilas G, Valavanis C, Kotoula V, et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicinbased dose-dense sequential chemotherapy. J Transl Med. 2012;10:10.
17. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327.
18. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8: 141-151.
19. Minca EC, Portier BP, Wang Z, et al. ALK status testing in nonsmall cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15:341-346.
20. Koletsa T, Kotoula V, Hytiroglou P, et al. Synovial sarcoma of the heart. Virchows Arch. 2004;444:477-479.
21. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013;119:1467-1477.
22. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 5′ and 3′ portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012; 18:4725-4732.
23. Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17:1351-1375.
24. Peters S, Taron M, Bubendorf L, et al. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer. 2013;81:145-154.
25. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105-1111.
26. Costa DB. Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer? J Clin Oncol. 2013;31:2236-2239.
27. Li Y, Pan Y, Wang R, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013;8:e69016.
28. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-1553.
29. To KF, Tong JH, Yeung KS, et al. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J Thorac Oncol. 2013;8:883-891.
30. Salido M, Pijuan L, Martinez-Aviles L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011;6:21-27.
31. Montgomery E, Argani P, Hicks JL, et al. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol. 2004;164:1523-1529.